ReviewPLoS medicine2012
HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making.
Review in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 72 citations in OpenAlex.
- Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.PloS one · 2016Trial
- Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire.The Journal of infectious diseases · 2014Trial
- Trial
- Trial
- Clinico-epidemiological characteristics of adolescents and young adults living with HIV in Ghana.The Pan African medical journal · 2024Article
- Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study.Clinical and molecular hepatology · 2023Article
- A Game Theoretic Analysis of Competition Between Vaccine and Drug Companies during Disease Contraction and Recovery.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation.Health economics review · 2021Article
- Development and dissemination of infectious disease dynamic transmission models during the COVID-19 pandemic: what can we learn from other pathogens and how can we move forward?The Lancet. Digital health · 2021Review
- Trends in human immunodeficiency virus diagnoses among men who have sex with men in North America, Western Europe, and Australia, 2000-2014.Annals of epidemiology · 2018Article
- Using Contact Patterns to Inform HIV Interventions in Persons Who Inject Drugs in Northern Vietnam.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa.Journal of the International AIDS Society · 2018Article
- Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS.Health economics review · 2017Article
- HCV prevalence can predict HIV epidemic potential among people who inject drugs: mathematical modeling analysis.BMC public health · 2016Article
- Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.The lancet. HIV · 2016Article
- Impact of Heterogeneity in Sexual Behavior on Effectiveness in Reducing HIV Transmission with Test-and-Treat Strategy.PLoS computational biology · 2016Article
- CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.Journal of epidemiology and community health · 2016Article
- Can a pill prevent HIV? Negotiating the biomedicalisation of HIV prevention.Sociology of health & illness · 2016Article
- Estimating mother-to-child HIV transmission rates in Cameroon in 2011: a computer simulation approach.BMC infectious diseases · 2016Article
- Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.The lancet. HIV · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.